Through regulation of the miRNA rs2431697 genotype and NLRP3, NF-κB1, and IL-1β genes, new therapeutic strategies could be considered to prevent myelofibrosis progression in MPN patients [107]. This evidence concerns the gene NLRP3 and myeloproliferative disorder.